Semi-Annual Consolidated Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7539685

Concept As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
As at
2022-09-30
2022-04-01 to
2022-09-30
As at
2022-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
3,703,000,000 JPY
1,907,000,000 JPY
Interest and dividends received
189,000,000 JPY
184,000,000 JPY
Interest paid
-21,000,000 JPY
-26,000,000 JPY
Income taxes paid
-774,000,000 JPY
-398,000,000 JPY
Net cash provided by (used in) operating activities
3,097,000,000 JPY
1,666,000,000 JPY
Cash flows from investing activities
Purchase of securities
-500,000,000 JPY
JPY
Purchase of property, plant and equipment
-639,000,000 JPY
-292,000,000 JPY
Purchase of investment securities
-299,000,000 JPY
JPY
Proceeds from sale of investment securities
2,883,000,000 JPY
56,000,000 JPY
Other, net
-14,000,000 JPY
58,000,000 JPY
Net cash provided by (used in) investing activities
1,382,000,000 JPY
-199,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-2,298,000,000 JPY
-1,149,000,000 JPY
Dividends paid
-226,000,000 JPY
-225,000,000 JPY
Net cash provided by (used in) financing activities
-2,539,000,000 JPY
-1,346,000,000 JPY
Other, net
-24,000,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
0 JPY
0 JPY
Net increase (decrease) in cash and cash equivalents
1,940,000,000 JPY
121,000,000 JPY
Cash and cash equivalents
19,446,000,000 JPY
17,505,000,000 JPY
17,224,000,000 JPY
17,103,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.